Subarachnoid hemorrhage, from ruptured intracranial berry aneurysms (Hunt and Hess Grades I-V)

Nimodipine is a calcium channel antagonist for the improvement of neurological deficits due to cerebral artery spasm following subarachnoid hemorrhage.

Protein binding: >95%; It crosses the blood-brain barrier, but concentrations in CSF are lower than those in plasma. Metabolism: Extensively hepatic via the CYP450 3A4 enzyme；Terminal elimination half-life: approximately 9 hr

hypersensitivity to nimodipine; Intravenous doses of nimodipine > 1mcg/kg/min (0.06 mg/kg/hr) may cause significant decreases in blood pressure and should be used with caution.

C

Enters breast milk/not recommended

Primary side effects are GI disturbance (diarrhea, nausea, and abdominal cramps). Reduction in blood pressure may also occur.

For subarachnoid hemorrhage, initial rate of 1 mg/hr for 2 hours, then 1-3 mg/hr (24-72 mg daily) for 1-2 weeks has been used. Dosage should be reduced in patients with hepatic function impairment.

Nimodipine is sensitive to light. Nimodipine solution can bind to polyvinyl chloride (PVC) tubing; non-PVC infusion equipment should be used. Nimodipine solution must not be added to an infusion bag or bottle, or be mixed with other drugs.